Trial · NCT00004562
Occluded Artery Trial (OAT)
NCT00004562, Phase 3, Completed, NYU Langone Health; results first posted 2013-02-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Occluded Artery Trial (OAT). Trials, record NCT00004562. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00004562
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Occluded Artery Trial (OAT)
- NCT number
- NCT00004562
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 2,201 participants, actual
- Lead sponsor
- NYU Langone Health
- Conditions
- Cardiovascular Diseases, Heart Diseases, Myocardial Infarction, Heart Failure, Congestive, Heart Failure
- Interventions
- Beta adrenergic blockers, Platelet inhibitors, PTCA and stents, ACE Inhibitors
- First posted
- 2000-02-10
- Last updated
- 2014-04-21
- Results first posted
- 2013-02-11
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) | Measured over a maximum 9-year follow-up period - 6 year median | Number of Patients with Events (death from any cause, nonfatal reinfarction, and hospitalization for New York Heart Association (NYHA) Class IV congestive heart failure). Events were centrally adjudicated. |
| Secondary | Number of Participants With Secondary Outcomes (Safety Events) | Measured over a maximum 9-year follow-up period - 6 year median | Number of Participants with Secondary Outcomes (death from any cause, nonfatal MI, class IV HF, cardiac death, occurrence of selected clinical outcomes including stroke, hospitalization for CHF, sustained ventricular tachycardia/ventricular fibrillation, ICD implantation, or the composite end point). Events were centrally adjudicated. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) | Measured over a maximum 9-year follow-up period - 6 year median | participants | NUMBER | |
| SECONDARY | Number of Participants With Secondary Outcomes (Safety Events) | Measured over a maximum 9-year follow-up period - 6 year median | participants | NUMBER |
Source ClinicalTrials.gov
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) | Percutaneous Coronary Intervention Group | 230 | participants | ||
| Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) | Medical Therapy Group | 219 | participants | ||
| Number of Participants With Secondary Outcomes (Safety Events) | Percutaneous Coronary Intervention Group | Death from all causes | 150 | participants | |
| Number of Participants With Secondary Outcomes (Safety Events) | Medical Therapy Group | Death from all causes | 153 | participants | |
| Number of Participants With Secondary Outcomes (Safety Events) | Percutaneous Coronary Intervention Group | Fatal and nonfatal reinfarction | 77 | participants | |
| Number of Participants With Secondary Outcomes (Safety Events) | Medical Therapy Group | Fatal and nonfatal reinfarction | 65 | participants | |
| Number of Participants With Secondary Outcomes (Safety Events) | Percutaneous Coronary Intervention Group | Nonfatal reinfarction | 75 | participants | |
| Number of Participants With Secondary Outcomes (Safety Events) | Medical Therapy Group | Nonfatal reinfarction | 61 | participants | |
| Number of Participants With Secondary Outcomes (Safety Events) | Percutaneous Coronary Intervention Group | NYHA class IV heart failure (HF) | 51 | participants | |
| Number of Participants With Secondary Outcomes (Safety Events) | Medical Therapy Group | NYHA class IV heart failure (HF) | 53 | participants |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Percutaneous Coronary Intervention Group | 1,101 | |
| Overall Study | STARTED | Medical Therapy Group | 1,100 | |
| Overall Study | COMPLETED | Percutaneous Coronary Intervention Group | 999 | |
| Overall Study | COMPLETED | Medical Therapy Group | 1,009 | |
| Overall Study | NOT COMPLETED | Percutaneous Coronary Intervention Group | 102 | |
| Overall Study | NOT COMPLETED | Medical Therapy Group | 91 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nonfatal reinfarction | Cardiac disorders | Percutaneous Coronary Intervention Group | 75 | 1,101 | 75 |
| other | Nonfatal reinfarction | Cardiac disorders | Medical Therapy Group | 61 | 1,100 | 61 |
| serious | Death from all causes | Cardiac disorders | Percutaneous Coronary Intervention Group | 150 | 1,101 | 150 |
| serious | Death from all causes | Cardiac disorders | Medical Therapy Group | 153 | 1,100 | 153 |
| serious | NYHA class III or IV Heart Failure | Cardiac disorders | Percutaneous Coronary Intervention Group | 76 | 1,101 | 76 |
| serious | NYHA class III or IV Heart Failure | Cardiac disorders | Medical Therapy Group | 74 | 1,100 | 74 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Percutaneous Coronary Intervention Group | ||
| Total, all-cause mortality | Medical Therapy Group | ||
| Total, other adverse events | Percutaneous Coronary Intervention Group | 75 | 1,101 |
| Total, other adverse events | Medical Therapy Group | 61 | 1,100 |
| Total, serious adverse events | Percutaneous Coronary Intervention Group | 226 | 1,101 |
| Total, serious adverse events | Medical Therapy Group | 227 | 1,100 |
Source ClinicalTrials.gov
Papers29
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL062509 | Occluded Artery Trial: Long Term Follow-Up | HOCHMAN, JUDITH S | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 1999 to 2010 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
Percutaneous Coronary Intervention Group vs Medical Therapy Group: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) | Trial comparisons |
| Percutaneous Coronary Intervention Group vs Medical Therapy Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00004562
GET https://conductscience.org/api/trials/v1/NCT00004562/papers?page=2